Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 14, 2025
Continued operational excellence leading to acceleration of multiple timelines:
ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025
Read more at globenewswire.com
